The plasma for fractionation (PPF) comes from a sampling by plasma-pherese or the taking of total blood after centrifugation and separation. Whatever its origin, the plasma for fractionation must be frozen and kept at a temperature of -40 degrees centigrade.
The medicines deriving from the plasma (MDP or MDS) are concentrations of human plasmatic protein characterised by:
Traceability is permanently organised and optimised, so that the plasmas for fractionation (PPF) and the final products originating from it (MDS) can be localised at any given time during the reception, storage and production industrial process.
To each sac of fresh plasma a radiofrequency electronic label (RFID) is attached, which allows data capture and reading all along the production chain, from the preparation of the PPF until the production of the MDS.
Furthermore, this flow makes the entirety of the intermediary phases of storage, transport and reception relevant by way of allowing "real time" control of information traceability.
The objective of the proceedings is to develop a global solution allowing it to optimise the production process (particularly in reception and sorting out phases) and the automatic traceability of the raw product (PPF) at the same time.
This objective has been achieved thanks to the development of "intelligent" equipment, the use of RFID labels (affixed onto all the PPFs) and important program and interface developments.
The solution allows simultaneous satisfaction of all the following needs:
What's new is the fact that the operators are able to efficiently control the information judged indispensable to their activity, thanks to major technological contributions, amongst which the more striking developments are:
Identification and traceability